Plendil Articles
AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million
2 March 2010
Mylan swings to a 2nd-qtr 2008 loss on Merck
18 August 2008
Final FDA appro for Mylan's felodipine
28 April 2008
Merck & Co sells JV products to AZ
10 March 2008
AstraZeneca may pay Merck & Co $3.3B
20 March 2006
AstraZeneca's EPS up 56%, sales rise 10%
1 November 2004
AstraZeneca sales rise 6.9% in 2nd quarter
5 August 2002
Cipla signs deal with IVAX affiliate
5 September 2001
AstraZeneca sales rise 8%, Nexium doing well
26 July 2001
AstraZeneca investing in China and India
30 April 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
Cipla mulls felodipine deal with Mutual
10 April 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
AstraZeneca sees 17% 1st qtr pretax growth
3 May 2000
AstraZeneca full-year profits up 20% as new products come good
24 February 2000
Astra sees fourth qtr sales leap 46% and rise 27% for full-year 1998
16 February 1999
Swedish pharma market sees 16.2% growth for 1998, says LIF
12 February 1999
Losec US sales up 35%, Astra to pay S-P $800m
27 January 1999
Losec US sales up 35%, Astra to pay S-P $800m
25 January 1999
Astra Merck's US Prilosec Sales Leap 80%
30 July 1998
HOT Study Helps Define Lower Blood Pressure Aim
15 June 1998
Strong 1st Qtr Growth In Swedish Pharma Market
15 May 1998
Losec Continues To Drive Astra Sales And Profits
29 April 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
Astra Merck Sales Of Prilosec Rise 32% In 4th Qtr 1997
28 January 1998
Parallel Import Challenge For Astra
28 January 1998
P&G Finalizes Deal With Astra Merck
13 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
Astra's Atacand Reaches First Market
26 November 1997
Astra Launches Lexxel
20 March 1997
Currency Exchange Affects 1996 Sales At Astra
24 February 1997
US Sales Of Astra's Prilosec Up 40% In 1996
10 February 1997
US Sales Of Astra's Prilosec Up 40% In 1996
31 January 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Astra Remains Strong In First Nine Months Of 96
11 November 1996
Encouraging HOT Study Results
8 July 1996
Omeprazole Sales Soar 57% In The USA
22 April 1996
Sweden's Pharma Market Expanded 12.7% In 1995
4 March 1996
Astra Merck Gets Bucindolol Rights
18 December 1995
Astra Strengthens R&D With Increased Spending
4 December 1995
Felodipine Of No Benefit But Does No Harm In CHF: Exercise Data
4 December 1995
HRG Seeks Calcium Antagonist Warnings
4 December 1995
33% Sales Growth For Astra
13 November 1995
Astra Posts Strong Growth Slightly Ahead Of Forecasts
4 September 1995
Calcium Blockers In Heart Failure: PRAISE Study
4 September 1995
JAMA Study Ups Debate Over Calcium Blockers
4 September 1995
Calcium Blockers In HF: V-HeFT III & DEFIANT II
4 September 1995
Congress Faces Generic Drug Pressure Over GATT
24 July 1995
Outstanding 1st Qtr Performance For Astra
22 May 1995
Felodipine Launch In Japan
17 April 1995
Astra Pretax Profit Rockets 23%, Fuelled By Losec
27 February 1995
Kissei/Ciba/Astra Agreement
20 February 1995
Japanese Year End Approvals
9 January 1995
Astra Updates On Its R&D Pipeline
5 December 1994
Strong Sales And Profits Growth At Astra
21 November 1994
Astra's Logimax Versus Enalapril
14 November 1994
Astra Merck: New Stand-Alone Company
7 November 1994
Astra's Logimax Could Be First-Line Therapy
7 November 1994
Losartan Gains First Approval In Sweden
10 October 1994
PH II RESULTS OF PROSCAR BALDNESS TRIALS
25 April 1994
LOGIMAX FOR INADEQUATE BLOOD-PRESSURE CONTROL
4 April 1994
STRONG 1993 RESULTS POSTED BY ASTRA
7 March 1994
SWEDISH PHARMA MARKET GROWTH SLOWDOWN
28 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
EXPANDING PHARMA MARKET IN TURKEY
10 January 1994
ASTRA BROADENS RESEARCH BASE
29 November 1993
POWERFUL GAINS AS ASTRA STRENGTHENS
22 November 1993
ASTRA'S ROXIAM HITS TOXICITY TROUBLE
8 November 1993
MERCK HITS TRIGGER FOR ASTRA BUSINESS
16 August 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
PRETAX PROFITS SOAR AT ASTRA
24 May 1993
CIBA-GEIGY Japan SETS CIBACEN GOAL
26 April 1993
SWEDEN'S PHARMA MARKET IN 1992
5 April 1993
PRETAX AND EPS SOAR AT ASTRA IN 1992
1 March 1993
FLODIL LP LAUNCHED IN FRANCE
12 October 1992
33% INTERIM PROFIT RISE AT ASTRA
7 September 1992
PLENDIL LAUNCHED IN GERMANY
7 September 1992
Astra 1991 results see losec boost
6 July 1992
HYPERTENSION OPTIMAL TREATMENT STUDY
22 June 1992
LOSEC SALES ROCKET FOR ASTRA
25 May 1992
ASTRA'S PLENDIL HEADING FOR CHF INDICATION
25 May 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
Showing 1-99 of 99 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
